Targets › CD3
24 programs from 19 companies in 31 trials: 29 Phase 1, 2 Phase 2; Oncology, Immunology, Hematology; next expected readout Nov 2026.
Open in Phaseline: the race on CD3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development | TQB2825 Injection CD3/CD20 bispecific antibody | CD3, CD20 | Phase 2 | Diffuse Large Cell B-lymphoma | Feb 2028 |
| Institute of Hematology & Blood Diseases Hospital, China | QLS4131 BCMA/GPRC5D/CD3 trispecific antibody | BCMA, GPRC5D, CD3 | Phase 2 | Primary Plasma Cell Leukemia | Dec 2029 |
| MacroGenics | MGD024 CD123 x CD3 bispecific DART molecule | CD123, CD3 | Phase 1 | Leukemia, Acute Myeloid | Nov 2026 |
| Lakefront Biotherapeutics West | OM336 Bispecific antibody targeting BCMA and CD3 | BCMA, CD3 | Phase 1 | AIHA - Warm Autoimmune Hemolytic Anemia; Sjogrens Disease | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group | TQB2825 injection CD20/CD3 bispecific antibody | CD20, CD3 | Phase 1 | Diffuse Large B Cell Lymphoma | Dec 2026 |
| Excyte Biopharma | YK012 Bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediate | CD19, CD3 | Phase 1 | Primary Membranous Nephropathy; B-cell Acute Lymphoblastic Leukemia; Systemic Lupus Erythematosus (SLE); Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Dec 2026 |
| Kali Therapeutics | KT501 Monoclonal antibody targeting CD19, BCMA and CD3 to deplete B cells and plasma cells | CD19, BCMA, CD3 | Phase 1 | Rheumatoid Arthritis (RA) | Feb 2027 |
| Johnson & Johnson (Janssen) | JNJ-80948543 T-cell redirecting trispecific antibody against CD79b, CD20, and CD3 | CD79B, CD20, CD3 | Phase 1 | Lymphoma, Non-Hodgkin | Mar 2027 |
| Memorial Sloan Kettering Cancer Center | Antithymocyte globulin (ATG) Polyclonal antibody targeting T lymphocytes; immunosuppressant | CTLA4, CD2, CD3, CD4, CD8 | Phase 1 | Myeloid Diseases; Hematologic Malignancies | May 2027 |
| Vironexis Biotherapeutics | VNX-101 Adeno-associated viral vector encoding CD3/CD19 bi-specific T-cell engager | CD3, CD19 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | Jun 2027 |
| OncoC4 | ONC-783 Bispecific antibody targeting CD24 and CD3 | CD24, CD3 | Phase 1 | Advanced Solid Tumor | Aug 2027 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | TQB2934 Anti-CD3 × BCMA double-specific antibody (bispecific T-cell engager) | CD3, BCMA | Phase 1 | Multiple Myeloma | Oct 2027 |
| Paul Szabolcs | CD3/CD19 negative hematopoietic stem cells Negatively selected hematopoietic stem cells depleted of CD3+ and CD19+ cells | CD3, CD19 | Phase 1 | Idiopathic Pulmonary Fibrosis | Dec 2027 |
| University of Virginia | EGFR FPBMC CD3 x EGFR bispecific antibody-armed fresh peripheral blood mononuclear cells | CD3, EGFR | Phase 1 | Pancreas Cancer | Dec 2027 |
| Kali Therapeutics | KT502 Monoclonal antibody targeting CD19 and CD3 for B cell depletion | CD19, CD3 | Phase 1 | Rheumatoid Arthritis (RA) | Dec 2027 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | TQB2029 for injection bispecific antibody targeting GPRC5D and CD3; recruits and activates CD3+ T cells to kill | GPRC5D, CD3 | Phase 1 | Multiple Myeloma | Mar 2028 |
| Shanghai EpimAb Biotherapeutics | EMB-07 Bispecific antibody targeting CD3 and ROR1 | CD3, ROR1 | Phase 1 | Combination Therapy | Jun 2028 |
| Antengene Biologics | ATG-201 Bispecific T-cell engager (TCE) binding CD3 and CD19 | CD3, CD19 | Phase 1 | Systemic Lupus Erythematosus | Dec 2028 |
| AstraZeneca | AZD6621 T cell-engaging antibody targeting STEAP2, CD3, and CD8 | STEAP2, CD3, CD8 | Phase 1 | Prostate Cancer | Mar 2029 |
| Cartography Biosciences | CBI-1214 Bispecific T cell engager targeting LY6G6D on colorectal cancer cells and CD3 on T cells | LY6G6D, CD3 | Phase 1 | Colorectal Cancer | Apr 2029 |
| Shanghai EpimAb Biotherapeutics | EMB-15 Bi-specific antibody against ALPP/ALPG and CD3; T-cell engager | ALPP, ALPG, CD3 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | May 2029 |
| University of Virginia | HER2 FPBMC Anti-CD3 x anti-HER2 bispecific antibody armed fresh peripheral blood mononuclear cells | HER2, CD3 | Phase 1 | Breast Cancer | Oct 2029 |
| Diane George | CliniMACS (PLUS) Reagent System (Miltenyi CliniMACS CD34+ Cell Selection Device) CD34+ cell selection device for T-cell depletion from peripheral blood stem cell transplan | CD34, CD3 | Phase 1 | Bone Marrow Failure Syndrome | Feb 2030 |
| Vironexis Biotherapeutics | VNX-202 Adeno-associated viral vector encoding CD3/HER2 bi-specific T-cell engager | CD3, ERBB2 | Phase 1 | HER2 Expressing Solid Tumors | Sep 2033 |
Lymphoma, Non-Hodgkin (3) B-cell Acute Lymphoblastic Leukemia (2) Multiple Myeloma (2) Rheumatoid Arthritis (RA) (2) Bone Marrow Failure Syndrome (1) Primary Membranous Nephropathy (1) Systemic Lupus Erythematosus (SLE) (1) Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (1) Advanced Solid Tumor (1) Breast Cancer (1) AIHA - Warm Autoimmune Hemolytic Anemia (1) Sjogrens Disease (1)
small molecule (15), other (3), mixed (3), protein or peptide (2), antibody (1)
University of Virginia (2) Vironexis Biotherapeutics (2) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (2) Shanghai EpimAb Biotherapeutics (2) Kali Therapeutics (2) Johnson & Johnson (Janssen) (1) Diane George (1) Excyte Biopharma (1) OncoC4 (1) Lakefront Biotherapeutics West (1) Paul Szabolcs (1) Memorial Sloan Kettering Cancer Center (1) Institute of Hematology & Blood Diseases Hospital, China (1) Antengene Biologics (1) AstraZeneca (1) Chia Tai Tianqing Pharmaceutical Group (1) Shanghai Chia Tai Tianqing Pharmaceutical Technology Development (1) Cartography Biosciences (1) MacroGenics (1)
CD19 (6) BCMA (4) CD20 (3) CD8 (2) GPRC5D (2) CD79B (1) CD34 (1) CD24 (1) HER2 (1) CTLA4 (1) CD2 (1) CD4 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.